Brandtree

Neurocrine: brands it owns and its ownership tree

Neurocrine (NASDAQ: NBIX) is a publicly listed company headquartered in San Diego, United States that owns 2 consumer brands.[1]

Neurocrine is a US neuroscience company. Its 2025 Form 10-K reports sales of Ingrezza and Crenessity.

Company facts

Legal name
Neurocrine Biosciences, Inc.
Headquarters
🇺🇸 San Diego, United States
Type
publicly listed company · all publicly listed company owners
Founded
1992
Tickers
NASDAQ: NBIX
Identifiers
SEC CIK 0000914475
Last verified
· 1 sources

Brands Neurocrine owns

2 brands in 1 category.

Drug makers (2)

  • Crenessity

    Biotechnology · 🇺🇸 United States

  • Ingrezza

    Biotechnology · 🇺🇸 United States

Full list of 2 brands with sources · Interactive ownership tree

Ownership structure

No company is recorded as controlling Neurocrine.

Who owns the shares of Neurocrine

Holders of more than 5% of the voting shares, as listed in Neurocrine's proxy statement filed 15 April 2026. Shareholdings change daily; this is the position the filing reports.

HolderSharesShare of class
BlackRock, Inc.12,052,27112%
The Vanguard Group10,129,68710.1%
Dodge & Cox5,534,6245.5%
JPMorgan Chase & Co.5,198,0845.2%

Financials and filings

Neurocrine financial history

Headline figures from Neurocrine's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $1.05bn to $2.86bn, an average of 22.3% a year (calculated).

Fiscal year endedRevenueOperating incomeOperating marginNet incomeTotal assetsLong-term debtFiling
$2.86bn $619.1m 21.6% $478.6m $4.63bn — 10-K
$2.36bn $570.5m 24.2% $341.3m $3.72bn — 10-K
$1.89bn $250.9m 13.3% $249.7m $3.25bn — 10-K
$1.49bn $249m 16.7% $154.5m $2.37bn — 10-K
$1.13bn $102.5m 9.0% $89.6m $2.07bn — 10-K
$1.05bn $163m 15.6% $407.3m $1.73bn — 10-K

Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.

Neurocrine SEC filings

The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.

Annual reports

Proxy statements

Recent current and quarterly reports

FiledFormWhat it declares
10-QQuarterly report
8-KResults of operations and financial condition
8-KDeparture or appointment of directors or officers
10-QQuarterly report
8-KResults of operations and financial condition
8-KDeparture or appointment of directors or officers; Results of a shareholder vote
8-KEntry into a material agreement; Completion of an acquisition or disposal of assets; Creation of a direct financial obligation; Regulation FD disclosure
10-QQuarterly report
8-KResults of operations and financial condition
8-KEntry into a material agreement
8-KResults of operations and financial condition
8-KDeparture or appointment of directors or officers
8-KResults of operations and financial condition

Neurocrine in the global legal-entity registry

The Global Legal Entity Identifier Foundation (GLEIF) keeps an open register of legal entities. Each entity reports its own parents. We show it as a cross-check on the ownership recorded on this page, which is built from filings.

Legal entity identifier (LEI)
549300FECER0XBN49756
Registered name
Neurocrine Biosciences, Inc. (US)
Registration status
Lapsed · record updated 29 July 2026
Parent
None named: its parent has not been disclosed publicly.
Retrieved
· GLEIF record (JSON)

Frequently asked questions

What brands does Neurocrine own?

Neurocrine owns 2 consumer brands tracked here, including Crenessity and Ingrezza.

Is Neurocrine an American company?

Yes. Neurocrine is headquartered in San Diego, United States and was founded in 1992.

Who owns Neurocrine?

Neurocrine is a publicly listed company owned by its shareholders; it trades as NBIX on the NASDAQ.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Neurocrine Biosciences, Inc. Annual Report on Form 10-K filed 2026-02-11 — SEC EDGAR, SEC Form 10-K, published 11 February 2026; retrieved 8 November 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.